Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 18, 2024 05:10 ET | Source: Research and Markets

Global Antidiabetics Market Report 2024 - A $313.9 Billion Market by 2034, with CAGR of 10.9% During 2024-2034

Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Antidiabetics Market by Product Type, by Application, by Distribution channel, and By Region" report has been added to ...
February 28, 2024 11:09 ET | Source: Research and Markets

JARDIANCE (Empagliflozin) Market Forecast Reveals Major Role in Myocardial Infarction Treatment and Competitive Landscape Analysis Through 2032

Dublin, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The "JARDIANCE Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. A comprehensive market...
March 06, 2023 09:48 ET | Source: Research and Markets

Global Diabetes Care Drugs Market to Reach $103 Billion by 2027: Asia-Pacific is Poised to Show a Considerable Growth Rate

Dublin, March 06, 2023 (GLOBE NEWSWIRE) -- The "Global Diabetes Care Drugs Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.The global diabetes care...
October 27, 2021 16:00 ET | Source: INVENTIVA

Inventiva annonce le design de LEGEND, un essai clinique de Phase IIa combinant lanifibranor et empagliflozine, un inhibiteur du SGLT2, chez des patients atteints de la NASH et de diabète de type 2

L’essai clinique LEGEND est un essai de Phase IIa de preuve de concept visant à évaluer la sécurité et l'efficacité de lanifibranor en combinaison avec empagliflozine, un inhibiteur du co-transporteur...
October 27, 2021 16:00 ET | Source: INVENTIVA

Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes

The LEGEND trial is a proof-of-concept Phase IIa clinical trial to evaluate the safety and efficacy of lanifibranor in combination with the sodium-glucose cotransporter 2 (SGLT2) inhibitor...